Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional enzyme involved in the base excision repair (BER) pathway, which repairs oxidative base damage caused by endogenous and exogenous agents. APE1 acts as a reductive activator of many transcription factors (TFs) and has also been named redox effector factor 1, Ref-1. For example, APE1 activates activator protein-1, nuclear factor kappa B, hypoxia-inducible factor 1a, paired box gene 8, signal transducer activator of transcription 3 and p53, which are involved in apoptosis, inflammation, angiogenesis and survival pathways. 
INTRODUCTION
A number of human pathologies, including cancer, neurodegenerative diseases (NDs) and cardiovascular disorders (CVDs), result from oxidative DNA damage caused by endogenous and exogenous agents, [1] [2] [3] as summarized in Figure 1 . The base excision repair (BER) pathway is the main repair pathway that repairs base damage (alkylation, oxidization, uracil, apurinic/apyrimidinic (AP) sites and strand breaks) in both the cell nucleus and mitochondria. 4, 5 AP site formation is central to this process and occurs spontaneously due to the attack of reactive oxygen species (ROS) or specifically due to the action of DNA glycosylase (DG). 6 AP endonuclease 1 (APE1), a multifunctional enzyme that is part of the BER pathway, exhibits DNA repair activity and has a role in the reductive activation of many transcription factors (TFs). 7 These two activities are encoded by two distinct regions of the APE1 protein: the N-terminal region encodes the redox function and the C-terminal region encodes the repair function. 8, 9 The DNA repair activity involves AP endonuclease activity, 3 0 phosphodiesterase activity, 3 0 phosphatase activity, and 3 0 -5 0 exonuclease activity 7, 10 and engages in protein-protein interactions with BER pathway proteins. 6, 11 APE1 physically interacts with BER pathway participant proteins, such as poly (ADP-ribose) polymerase 1 (PARP1), 12 X-ray repair cross-complementing protein 1 (XRCC1), 13 DNA polymerase b, 14 flap endonuclease 1 (FEN-1) and proliferating cell nuclear antigen 15 to stimulate individual proteins with which it interacts; thus, APE-1 coordinates the BER pathway. 6 APE1 has another important function, in which respect it is also known as the redox effector factor 1 (Ref-1). 7 APE1/Ref-1 reductively activates TFs including c-Jun, activator protein-1 (AP-1), nuclear factor kappa B (NF-kB), the tumor-suppressor protein p53, hypoxia-inducible factor 1a (HIF-1a) and paired box gene 8, which are involved in various cellular processes such as cell survival, growth signaling and inflammatory pathways. [16] [17] [18] [19] [20] The mechanism by which APE1/Ref-1 reduces the cysteine (Cys) residues of these TFs involves the exchange of a proton (H þ ion) from one or two of the redox active Cys residues in its N-terminus (Cys65, Cys93, Cys99 or Cys138), thereby activating their DNAbinding activity. 7, 21 Specific redox-dependent and redox-independent physical protein-protein interactions are also mediated by APE1/Ref-1 to carry out other biologically relevant cellular functions such as that involving Werner (WRN) protein, which is involved in premature aging; 22 ERp57 (endoplasmic reticulum-associated p57 (thiol-disulfide oxidoreductase)) protein, which is involved in the disulfide shuffling of glycoproteins; 23 Y-boxbinding protein 1 (YB-1), which causes the activation of the multidrug resistance (MDR1) gene; 24, 25 and various neuronal proteins (such as pyruvate kinase 3 isoform 2 (PKM2), tropomodulin 3 (Tmod3) and heterogeneous nuclear ribonucleoprotein-H1 (hn-RNP-H)), which are involved in neuronal cell survival after amyloid beta (Ab) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) peptideinduced stress-dependent events. 26 APE1/Ref-1 dysregulation has been associated with neurodegenerative [27] [28] [29] [30] and CVDs 31 and with various human cancers. [32] [33] [34] [35] [36] [37] APE1/Ref-1 may have a role in cancer progression via its ability to increase DNA repair and anti-apoptotic, inflammatory and growth-promoting activities. 21, 34 In NDs, decreases in the activities of APE1/ Ref-1 contribute toward disease progression, and neuronal cell survival is aided by increasing or protecting APE1/Ref-1's activities. 26 DNA damage and repair can have a key role in cancer therapy-induced neurotoxicity; to establish that such a phenomenon exists, Englander's group demonstrated the role of APE1/Ref-1 in chemotherapy-induced peripheral neuropathy (CIPN). Peripheral nervous system (PNS) neurons were shown to be vulnerable to circulating toxin/inflammatory mediator/ anticancer agent-induced DNA damage due to the permeability of the PNS blood-nerve barrier. 38 Thus, CIPN can obstruct anticancer treatment goals. This obstruction can be overcome by improving DNA repair fidelity in PNS neurons. Another study has observed the overexpression and localization of DNA repair proteins (including APE1/Ref-1) in antimitotic agent-induced damage to dorsal root ganglia (DRG) neurons and noted the potential for using various repair proteins for use as biomarkers and for the reversal of cancer therapy-induced damage; further, they noted that these proteins can be exploited for use in predicting post-treatment risks in PNS neurons. 39 Despite 41 This 36.5-kDa protein is encoded by a 3-kb gene, which is located on chromosome 14. 42 The active site for the DNA repair function of APE1/Ref-1 is located within the C-terminal domain; three residues in this domain (Phe266, Trp280 and Leu282) form a hydrophobic pocket that recognizes and captures the AP site. APE1/Ref-1 is a rate-limiting enzyme in BER pathway; the efficiency of the fast step of incision at the AP site can be limited by slow product release. 43 The enzyme works by first inserting its loop into both the major and minor grooves of DNA, then flipping the AP nucleotide into its hydrophobic pocket and finally kinking the DNA helix. 44, 45 The N-terminus contains a nuclear localization signal that is crucial for redox activity. 7,45-47 APE1/Ref-1 has a role in distinct transcriptional regulatory functions by acting as a reductive activator of TFs and acting as a redox-independent transcriptional repressor of some genes. [17] [18] [19] [20] [21] Oxidative damage to both DNA and RNA (including messenger RNA, ribosomal RNA and transfer RNA) have been associated with various diseases. 48 Recently, APE1/Ref-1's role in RNA metabolism (including its function as a riboendonuclease) has been identified, showing that it has a role in the posttranscriptional regulation of gene expression. 49, 50 Therefore, 55 Following removal of the blocking group (dRP) by the dRP lyase activity of DNA pol b, DNA repair is completed by the action of DNA ligase, thus restoring genome integrity. 56 The bifunctional DGs with additional intrinsic AP lyase activity cleave the DNA strand 3 0 to the AP site, thereby generating a 3 0 blocking group. 57, 58 The resulting 3 0 blocking group is then removed by the APE1/Ref-1 enzyme (or in some cases, by polynucleotide kinase). 41, 59 The 3 0 phosphodiesterase activity of APE1/Ref-1 is also involved in repairing single-strand breaks in DNA, and a 3 0 blocking group is directly generated by ROS. 60 Unrepaired AP sites can lead to DNA strand breaks, apoptosis and increased cytotoxicity. 61 Therefore, the DNA repair function of APE1/ Ref-1 is indispensable in protecting the cell from both endogenous and exogenous DNA damage. All APEs possess both endonuclease and 3 0 phosphodiesterase activity. 53, 54 However, the mammalian endonuclease activity of APE1/ Ref-1 is stronger than its 3 0 exonuclease/phosphodiesterase activity. 41, 53 Furthermore, unlike Escherichia coli exonuclease III (xthA), which exhibits potent 3 0 phosphatase/ Figure 3 A schematic representation of the mechanism of the short-patch (SN-BER) and long-patch (LP-BER) sub-pathways of base excision repair (BER) in mammalian cells. apurinic/apyrimidinic endonuclease 1 (APE1)/redox effector factor-1 (Ref-1) functions as an AP endonuclease in SN-BER, initiated by monofunctional DNA glycosylase (DG), and as a 3 0 phosphodiesterase in LP-BER, initiated by bifunctional DG. Pol b, X-ray repair cross-complementing protein 1 (XRCC1) and ligase III are required for SN-BER to conduct SN repair, whereas proliferating cell nuclear antigen (PCNA), Pol d/e, flap endonuclease 1 (FEN-1) and ligase I are required for LP-BER to conduct multinucleotide repair in mammalian cells.
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S Thakur et al phosphodiesterase activities, mammalian APE1/Ref-1 exhibits extremely weak 3 0 phosphatase activity, which is required to remove 3 phosphate groups that are directly generated by ROS or that result from the AP lyase activity of mammalian DGs, NEIL1 (endonuclease VIII-like 1) and NEIL2. 62, 63 The role of APE1/Ref-1 in redox regulation Redox potential controls gene expression by regulating the DNA-binding activity of TFs. 7 APE1 is also known as Ref-1 because of its role in the redox regulation of the DNA-binding activity of various TFs. 7 The ability of Ref-1 to facilitate the DNA-binding activity of AP-1 was identified in HeLa cells. 20 A thiol exchange reaction was found to be involved in the reductive activation of c-Jun by reduced APE1/Ref-1, in which the Cys272 of c-Jun is first oxidized to sulfenic acid (SOH) and then reduced by Cys65 of APE1/Ref-1 to the active form. 20 The resultant oxidized form of APE1/Ref-1 is then reduced by thioredoxin (TRX), and oxidized TRX is reduced by TRX reductase. 64 Seven Cys residues have been reported as conserved in mammalian APE1. Of the seven Cys residues, three (Cys65, Cys93 and Cys99) are considered important for redox function. 65 Cys65 and Cys93 are buried and surface inaccessible, whereas Cys99 is solvent accessible. A study by Walker et al. 66 reported that Cys65 is essential for redox function in vitro. In this study, each of seven Cys residues was substituted by Ala singly, and each mutant was then tested for redox activity. Only Cys65Ala lost redox activity. Cys93Ala retained redox activity but at significantly lower levels than in wild-type (WT) APE1. A possible explanation for the redoxinactivity of the Cys65Ala mutant may be a change in the stability and folding of APE1. 67 Nuclear magnetic resonance (NMR) evidence demonstrated that TRX interacts with a Cys65-containing polypeptide at the active site. 68 A study showed that the Cys65 mutant acts as a dominant-negative inhibitor of the redox function of selenomethioninecontaining APE1/Ref-1. 69 Furthermore, the apoptosis of neurons after oxidative stress has been shown to be prevented by ectopic WT APE1/Ref-1 expression and also, but to a smaller extent, by the Cys65Ala mutant. 70 Moreover, several studies using TF-dependent reporter expression assays have shown that the Cys65 mutant does not behave like WT APE1/Ref-1. [71] [72] [73] However, the proposed Cys65-mediated redox function of APE1/Ref-1 was challenged by Curran's group, 74 which showed that homozygous Cys64Ala (in humans, Cys65) knock-in mouse APE1/Ref-1 mutants are viable and retain normal levels of AP-1 DNA-binding activity. Furthermore, the recombinant Cys64Ala mutant exhibited normal c-Jun reducing activity, similar to that exhibited by WT APE1/Ref-1 in vitro. 74 Another study showed that APE1/Ref-1 stimulates p50 or c-Jun DNA-binding by facilitating their reduction by reducing agents such as glutathione or TRX, and none of the Cys residues in APE1/ Ref-1 were found to be essential for this activity. 75 These findings challenge the role of Cys64/65 in the redox function of APE1/Ref-1. However, these findings have been disproved by some recent studies. Luo et al. 76 discovered that Thr58 is equivalent to Cys65 in zebrafish. It was observed that substituting Thr58 for Cys in the zebrafish enzyme confers a redox function, as found using in vitro assays and transactivation assays. 77 Another study by Vascotto et al. 78 has also indicated that Cys65 has a role in controlling APE1/ Ref-1 sub-cellular functions. Double-cysteine mutants have been also analyzed to determine whether other Cys residues have roles in the redox activity. All double-cysteine mutants except Cys93Ala/Cys99Ala displayed redox activity. 65 This study further suggested that other Cys residue(s) of APE1 may have a role in the redox mechanism.
Specific redox inhibitors and mass spectral (MS) analysis have also been used to characterize the detailed mechanism and redox active form of APE1/Ref-1. In this context, E3330 has been used in various studies, and the mechanism of interaction between E3330 and APE1/Ref-1 has remained a subject of interest. 77, 79 In one of the studies by Zhang et al. 80 using MS and N-ethylmaleimide (NEM) labeling, it was concluded that E3330 interacts with partially unfolded APE1/Ref-1. In chemical foot-printing experiments with NEM, the incubation of APE1 with E3330 yielded fully modified APE1/Ref-1 protein; that is, all seven Cys residues were labeled with NEM. As previously mentioned, only two of the seven Cys residues are solvent accessible, therefore, APE/Ref-1 may be unfolded in the presence of E3330. Cys65, which is normally buried and is critical for the redox function of APE1/Ref-1, also becomes exposed and reacts with NEM in the presence of E3330. Furthermore, based on experiments using tandem MS and liquid chromatography, the E3330-mediated increase in disulfide bond formation of the critical Cys residues Cys65 and Cys93 of APE1/Ref-1 has been suggested as the cause of the inhibition of redox activity. 81 The transcriptional activity of AP-1 is regulated by the direct interaction of APE1/Ref- 1 24 leading to activation of the MDR1 gene. It appears that an acetylation-mediated conformational change occurs in the disordered N-terminal segment (B40 residues) of APE1/Ref-1 and that this conformational change is required for endonuclease activity and the modulation of protein-protein interactions. 24, 25, 91, 92 Potential phosphorylation sites on APE1/Ref-1 include consensus sequences for casein kinase I/casein kinase II (CKI and CKII) and protein kinase C (PKC). PKC phosphorylation has been shown to stimulate the redox activity of APE1/Ref-1 in vitro. 85, 93 Moreover, CKII-mediated phosphorylation abolished DNA repair activity in vitro, whereas phosphorylation by CKI or PKC had no such effect. 94 Further, the phosphorylation of APE1/Ref-1 by CKII also enhanced the redox activation of the TF, AP-1. 95 APE1/Ref-1 was found to be phosphorylated at Thr233 by the threonine kinase cyclindependent kinase 5 (CDK5), a paralog of CDK2/4. 28 A high level of phosphorylated Thr233 was observed in brain tissues from PD and AD patients. 28 It is possible that the inactivation and degradation of APE1/Ref-1 by phosphorylation and subsequent ubiquitination may profoundly affect the severity of various human diseases.
Ubiquitination has been demonstrated to have a role in regulating the steady-state levels of BER enzymes in mammalian cells by directing their degradation and turnover. 96 Ubiquitin is a highly conserved small protein (B8.5 kDa), the covalent addition of which to a target protein as a polymer by ubiquitin ligases promotes the latter's degradation by the 26S proteasome. 97 However, ubiquitinated proteins may also be recycled by the removal of ubiquitin by deubiquitinases or by ubiquitin-specific proteases. 98, 99 Proteins may be ubiquitinated with a single ubiquitin moiety (monoubiquitination) or with multiple ubiquitin molecules (polyubiquitination). Recently, it has been demonstrated that APE1/Ref-1 ubiquitination, which is enhanced by phosphorylation at Thr233, 100 can act as a signal to regulate the stability, subcellular localization and gene regulatory functions of APE1/Ref-1. 93, 98 The specific interaction(s) between APE1 and TRX require the translocation of TRX from the cytoplasm to the nucleus, 101 which can be induced by oxidants, cytokines and ultraviolet irradiation. 102, 103 The results of one study indicate that APE1/ Ref-1 promotes cell proliferation by acting as a direct redox regulator of extracellular signal-regulated kinase. 104 Together, these studies suggest that APE1/Ref-1 is an essential enzyme that is responsible for the redox regulation of various TFs, either directly or indirectly, while involving other reducing factors.
The role of APE1/Ref-1 in maintaining cellular homeostasis Cellular homeostasis is maintained through the balancing of cellular redox states. Any imbalance causes oxidative stress in cells. Cellular redox state is regulated by ROS/reactive nitrogen species (RNS) and enzymatic/non-enzymatic antioxidant systems. 105, 106 ROS/RNS have significant roles in maintaining cellular redox states because they are continuously generated in cells during normal metabolism as respiration by-products and during inflammatory responses. [107] [108] [109] Physiologically, low basal levels of ROS/RNS are involved in intracellular signaling as second messengers, whereas high levels of ROS/ RNS cause oxygen and nitrogen toxicity. 107, 110 ROS can also be induced exogenously by environmental agents such as heavy metals, ionizing radiation and chemotherapeutic drugs. 111, 112 RNS, such as nitric oxide (NO Á ), are generated by NO synthase (NOS), endothelial NOS (eNOS), neuronal NOS and inducible NOS. On reaction with O 2 À , NO Á forms peroxynitrite (ONOO À ), a more potent form of RNS. 113 Ab peptide, which accumulates in Alzheimer's disease (AD), generates ROS in presence of transition metal ions. 114 On reaction with cellular components, accumulated ROS/RNS confer genotoxic effects and induce several DNA lesions including oxidized bases, AP sites and DNA strand breaks. 115 Therefore, the cellular redox state requires balancing by the reduction of abnormally raised ROS levels. It has been demonstrated that ROS activates APE1/Ref-1 expression, and activated APE1/Ref-1 has been shown to be responsible for the adaptive response of ROS-treated cells via elevated-APE1/Ref-1-mediated increases in endonuclease activity. 86 In response to oxidative stress, increases in the endonuclease activity of elevated APE1/Ref-1 have been shown to confer resistance to human glioma cells toward alkylating agents. 116 It has been demonstrated that APE1/Ref-1 modulates the cellular redox state via the inhibition of intracellular ROS production or by binding with TFs, such as p53 and HIF-1a. 117 A study by Hafsi and Hainaut 118 reported that p53 is responsible for the regulation of redox-dependent physiological processes. Redox-sensitive p53 is regulated by ROS and in turn, activated p53 (that is, p53 that is directly activated by ROS or via redox factors, such as APE1/Ref-1) influences ROS production. 119 In support of this finding, a previous study demonstrated that APE1/Ref-1 regulates cellular oxidative stress by controlling Rac1 GTPase activity and protects against oxidative cell death. 120 68 In previous studies, NMR experiments and yeast twohybrid systems have provided evidence for such interactions. 82, 123 APE1/Ref-1 was shown to act as a reductive activator of the tumor-suppressor protein p53, which migrates to the nucleus when activated, where it activates the transcription of responsive genes. 84 In an another study, APE1/Ref-1 (for redox regulation) was shown to interact stably with HIF-1a to maintain the Src-dependent, hypoxia-induced expression of vascular endothelial growth factor in pancreatic and prostrate carcinomas. 124 An in vitro study showed enhanced APE1/Ref-1's endonuclease activity at AP sites due to physical interactions between APE1/Ref-1 and hsp70 upon oxidative stress. 121 In addition, APE1/Ref-1 and the WRN protein, the deficiency of which is involved in premature aging, have been shown to interact. 22 APE1/Ref-1 stimulates the DNA-binding activity of p53 in a redox-independent manner by promoting the association of dimers into tetramers (that is, p53 tetramerization). 125 APE1/Ref-1 has been demonstrated to interact with the p53 activator, Cdk5. 28 APE1/Ref-1 has also been shown to stably interact with signal transducer activator of transcription 3 (STAT3) and p300 in some studies. 47, 124, 126 In response to oxidative stress, nuclear APE1/Ref-1 interacts with ERp57, an endoplasmic reticulum (ER) protein involved in the folding and disulfide shuffling of glycoproteins and in the assembly of the major histocompatibility complex. 23 Stable interaction between APE1/ Ref-1 and YB-1 results in MDR-1 gene activation. 25 The known protein-protein interaction(s) by which APE1/ Ref-1 has a role in various biological functions are summarized in Table 1 . Our recent study has identified various proteins that interact with APE1/Ref-1-interacting proteins (Figure 4 ) that are associated with functions required for neuronal cell HIF-1a 21 
5
C R E B 21 6 A P -1( c -J u n ) 21 
7
P a x -8 21 
8
S T A T 3 7,161 9 p 3 0 0 7 10 HDAC1 7
Other proteins 1 Y B -1 24 2 a n t i -N G F3 0 26 
BIOLOGICAL REDOX BALANCING AGENTS AND CROSSTALK WITH APE1/REF-1 Intracellular antioxidants
Enzymatic and non-enzymatic antioxidants provide protection against various oxidants that are generated by aerobic metabolism. 127 Cellular oxidative stress results from an imbalance between oxidants and antioxidants. Antioxidants slow down or prevent oxidative reactions that generate toxic metabolites, such as free radicals, which begin a cascade of reactions that results in cell damage. 128 Oxidants, such as ROS/RNS, have both beneficial and deleterious effects on organisms depending upon whether their levels are normal or abnormal. 129 To maintain the appropriate balance, various non-enzymatic antioxidants (such as glutathione, vitamin C and vitamin E) and enzymatic antioxidants (such as superoxide dismutase (SOD), catalase (CAT) and peroxidases) are produced in the body. These antioxidants function in three defense processes:
(1) prevention, (2) scavenging and (3) repair. 127 For this, antioxidants need to interact or crosstalk with key proteins involved in these defense processes. APE1 Parkinson's disease. PD is a common motor neurodegenerative disorder that is associated with a progressive loss of Amyotrophic lateral sclerosis. ALS is another ND that is characterized by progressive weakness and muscular atrophy. An elevated concentration of intracellular-free radicals that leads to motor neuron degradation has been identified as one of the causal factors of this disease. 144 In sporadic ALS, reduced expression and repair activity of APE1/Ref-1 have been observed. 145 In an another study, APE1/Ref-1 levels were found to be elevated in the brain and spinal cord samples of patients with ALS, indicating the possible activation of DNA damage repair mechanism(s) through the BER pathway; this activation may be an upstream mechanism for motor neuron degeneration in ALS 139 in cases where the mechanisms for DNA repair may be exhausted upon the prolonged stimulation of degenerative cascades. In addition, analyses of cloned APE1/Ref-1 transcripts from nine ALS patients and two patients (twins) with familial ALS revealed five-amino-acid substitutions: Leu104Arg, Glu126Asp, Asp148Glu, Asp283Gly and Gly306Ala. 146 All of these SNPs were observed once, excluding Glu126Asp, which was reported in both twins with familial ALS; however, no amino-acid changes in APE1/Ref-1 were detected in five healthy controls. In an independent study, an APE1/Ref-1 Asp148Glu variant, which was found in both ALS and control samples, was shown to be associated with sporadic but not familial ALS. 146, 147 Cerebral ischemia. Cerebral ischemia is caused by a blood supply to the brain, which results in oxidative stress in neuronal cells. In a study, elevated levels of APE1/Ref-1 were correlated with neuronal survival against ischemic insult, although the results depended on the central nervous system (CNS) region examined, the protective treatment applied and the degree of insult. 140 Neurons with decreased APE1/Ref-1 expression and endonuclease activity were found to be extremely vulnerable to cell death induced by in vitro ischemia, indicating that oxidative base lesions and AP sites can trigger ischemic cell death. 148 In another study, oxidative stress-mediated increased APE1/Ref-1 expression was observed in the hippocampus of rat brain in response to global cerebral ischemia/traumatic brain injury/cold injury; this observation was associated with neuronal apoptosis in rats. 149, 150 Perspectives on cancer Cancer is defined as the uncontrolled growth of abnormal cells in the body and is caused by abnormalities in various mechanisms including deletion, amplification or mutation in the genetic material. Two principal modalities for the prevention and cure of cancer exist; early detection and efficient treatment. First, for early detection, possible candidate genetic markers should exhibit altered expression patterns in cancerous cells when compared with healthy normal cells. Second, for prevention and treatment, two further main approaches are used to prevent or cure cancer: (a) obstructing the cancer at the very first error that occurs during the initial phase (that is, at initiation) and (b) forestalling all the possible molecular pathways by which the cancer sustains its own survival (that is, during growth, progression and metastasis). 151 The first approach, which appears more direct and obvious than the later, and perhaps is more difficult to achieve, hence not yet been developed for therapeutic use. Therefore, the second approach is exploited more widely in current research. Moreover, blocking a single molecular pathway is insufficient in most cases because different types of cancer appear to be heterogeneous. 155 The coordination between the expression pattern of APE1/ Ref-1 and its subcellular location has differed among different cell types studied thus far. Normally, APE1/Ref-1 is predominantly expressed within the nucleus rather than in the cytoplasm. Cytoplasmic expression is mainly observed in cell types exhibiting active metabolism associated with the cell organelles mitochondria and ER, in response to oxidative stress. 88 Altered APE1/Ref-1 subcellular localization patterns (mixed localization or predominant nuclear or cytoplasmic localization) have been observed in many cancers. Positive nuclear APE1/Ref-1 expression has been observed in head and neck cancer, in rhabdomyosarcomas, bladder, ovarian, gastroesophageal and pancreatico-biliary cancers. 32, [156] [157] [158] Positive cytoplasmic APE1/Ref-1 expression has been observed in some cancers, such as thyroid, prostate and hepatocellular cancers. 33, 36, 159 More localized distribution of APE1/Ref-1 was observed in non-small cell lung cancer cell. 37 In addition, upregulated APE1/Ref-1 expression levels were found to be associated with poor prognosis in medulloblastoma. 160 A positive correlation between aggressive tumor grade and nuclear APE1/Ref-1 expression in ovarian, gastro-esophageal and pancreatico-biliary cancers was observed. 32 Nuclear localization was also found to be associated with cellular differentiation pattern and lymph node status. 36 163, 164 These findings are also suggestive that APE1/Ref-1 expression levels can be used as a predictive marker for treatment response. 163 Although immunohistochemistry analyses and siRNA knock-down studies are able to provide sufficient information regarding the role of APE1/Ref-1 in normal versus cancerous cells, these studies do not reveal the significance of the individual repair or redox activities of APE1/Ref-1. However, the identification of causal activity (modulated repair or redox activity) in cancer risk is critical for further research and therapeutic applications.
Malignant gliomas are most common primary, intracranial tumors in adults and are often fatal forms of brain cancer, with a 2-year survival rate of B26%. 165 Treatment options for gliomas include surgical resection followed by chemotherapy or radiation, both of which generate lesions that are repaired by different repair pathways. The high-throughput screening of 60 000 small-molecule compounds has led to the identification of several small-molecule inhibitors of endonuclease activity. Of these screened small compounds, ARO3 stands out the most promising inhibitor of endonuclease activity in glioma therapy. 165 Substantially elevated levels of APE1/Ref-1 and enhanced endonuclease activity are characteristic of adult gliomas. 154 APE1/Ref-1 endonuclease activity was found to be significantly greater in high-grade tumors than in low-grade tumors. 154 Glial cell-derived neurotrophic factor (GDNF) is a neurotropic factor that is specific for the survival and differentiation of mid-brain DRG neurons. It has been reported that APE1/Ref-1-stimulated, GDNF/GDNF family receptor alpha 1 (GFRa1)-mediated downstream signaling enhances the proliferation of neuroblastoma cells; 166 challenging the current therapeutic strategies used against gliomas.
To identify the role of APE1/Ref-1 repair activity in cancer progression, certain selective inhibitors have been used. In one such study, APE1/Ref-1's repair activity was found to provide resistance to glioblastoma cells against alkylating agents. 116 In another study, it was found that the inhibition of endonuclease activity sensitized breast cancer cell lines to temozolomide. 152 The novel small-molecule-based inhibitor of APE1/Ref-1's redox activity, E3330, was found to block the redox activation of the TF AP-1; thus, E3330 increased the sensitivity of ovarian cancer cells toward alkylating agents. 167 It was further demonstrated that when administered along with methoxyamine, which blocks repair activity, tumor cell killing is markedly enhanced. 167 It was also found that E3330 abolishes the role played by APE1/Ref-1 in angiogenesis. 76 Further research utilizing selective inhibitors against the individual functions of APE1/Ref-1 is required to delineate the underlying cause to enhance the current therapeutic potential toward various cancers. [168] [169] [170] [171] [172] [173] Another SNP, 656 T4G, which lies in the promoter region of the APE1/Ref-1 gene, is associated with lung cancer risk. 174 The homozygous SNP, 656 T4G, is associated with renal cell carcinoma. 175 Reduced endonuclease activity has been reported in four of seven identified APE1/Ref-1 variants. 146 Most of these studies were population based, so it is possible that certain factors such as environmental conditions, dietary lifestyle or heterogeneity among populations can act as effect modifiers. 146 
Perspectives on CVDs
CVDs are the leading cause of death worldwide; the major manifestations of CVD include myocardial infarction, coronary artery disease, stroke and peripheral artery disease. 176 During 2008, 244 deaths were recorded because of CVD per 10 000 individuals according to a report published by the American Heart Association. 177 Hypertension affects 450 million Americans and 65% of people older than 65 years. 178 Various DNA-repair gene polymorphisms are associated with CVD. 179 Several studies have shown an association between the DNA-repair enzyme APE1/Ref-1 and CVD, but the molecular mechanism(s) involved require further study.
In an investigation performed on aortic coarctation-induced hypersensitive rat models, APE1/Ref-1 expression was found to be elevated. 31 In an another study, an association between APE1/Ref-1 gene polymorphism and essential hypertension was observed. 135 A study was carried out using the COS-7 cell line and an APE1/Ref-1 þ / À mouse model to study the role of endogenous APE1/Ref-1 in the regulation of endotheliumdependent vascular tone and systemic blood pressure. 71 Damaged endothelium-dependent vascular relaxation due to reduced eNOS activity and basal endothelial NO production was observed in APE1/Ref-1 þ / À mice relative to WT mice. 71 The stimulation of eNOS activity was not caused by APE1/Ref-1 overexpression. However, the nuclear localization of APE1/ Ref-1 was critical for the stimulation of eNOS expression. APE1/Ref-1 can also act as a promising candidate in preventing the neurotoxicity caused by cancer therapeutics in terms of the attenuation or reversal of therapy-induced damage. 38 Englander 39 reported the overexpression and localization of DNA repair proteins in DRG neurons damaged by antimitotic agents. These authors suggested that such DNA-repair proteins can be used to predict posttreatment risks in PNS neurons and can help to overcome neurological side-effects such as CIPN that has been caused by cancer therapeutics. Further studies are required to determine new therapeutic strategies that may aid in enhancing the DNA
repair functions of nuclear and mitochondrial BER enzymes in neurons. 5 Another role of APE1/Ref-1 has been observed in agerelated macular degeneration and other eye-related diseases. Neovascularization in the retina is a key pathology in several ocular diseases, such as age-related macular degeneration, diabetic retinopathy and retinopathy of prematurity, 184 
Soy isoflavones
Radiation therapy is used for the effective treatment of cancer but has adverse effects on normal cells. Soy isoflavones have been reported to exert a cytotoxic effect on cancer cells 187 and can be used as dietary modulators for the treatment of cancer and other diseases. Increased DNA-repair enzyme activity has been observed in lung cancer cells, and complementary treatment with soy isoflavones rendered these cells more sensitive to radiation therapy. 186 Inhibition of the radiationenhanced repair and redox activities of APE1/Ref-1 promoted the effective use of isoflavones in association with radiotherapy. 188 Simultaneous treatment with soy isoflavones not only decreases the survival rate of cancer cells but also prevents other cells from the adverse effects of radiotherapy by improving their physiological state. 189 This may be due to increased APE1/Ref-1 repair activity in the normal cells (which contrasts with its downregulation in cancer cells). However, no study has measured the APE1/Ref-1 levels thus far. Genistein and daidzein are components of soy extracts that exhibit contrasting properties. Genistein increases metastasis whereas daidzein inhibits metastasis in the lymph nodes by affecting APE1/Ref-1 levels and the levels of other TFs in prostate cancer cells. 190 In contrast, genistein when used alone, sensitizes prostate cancer cells to radiotherapy. 191 Therefore, pure components and their analogs could be used as drug targets in the development of cancer therapeutics. In addition, APE1/Ref-1 downregulation by soy extracts rendered pancreatic and oral cancer cells more responsive toward radiotherapy. 134, 187 Further experimental studies are advocating for the role of soy isoflavones in the improvement of memory and mental health. 192 Soy isoflavones can prevent oxidative stress and reduce the damaging effects caused by aging and AD. 193 Dose-dependent effect of soy isoflavones was observed in D-galactose-treated, aging-induced C57BL/6J (B6) mice, where DG-induced Ab and presenilin I expression was found lowered by soy isoflavones in the B6 mice. 193 Genistein also showed protective effect on the cortical neurons with iron-induced lipid peroxidation and toxicity. 194 These soy isoflavones proved to provide neuroprotection under both in vitro and in vivo conditions by ER-mediated pathway and tyrosine kinase inhibition. 195 Resveratrol Resveratrol (trans-3 0 ,4 0 ,5-trihydroxystilbene) is an important polyphenolic antioxidant present in grapes and other dietary components. 153 Resveratrol exhibits antiproliferative activity against cancer cells, which has been well elucidated using in vitro studies. 153, 196, 197 153 In addition, it was also found that the dose-dependent inhibition of APE/Ref-1 expression by resveratrol rendered melanoma cells are more susceptible to the action of drugs such as dacarbazine. 153 Resveratrol also has an important role in the prevention of stress by modulating APE/Ref- 1. 198 Aluminum chloride (AlCl 3 )-induced neuroinflammation in rat brain was prevented by treatment with resveratrol, and elevated levels of APE1/Ref-1 were suggested as the main cause of the prevention of toxicity to the neuronal APE1/Ref-1 as an emerging therapeutic target S Thakur et al cells, together with the expression of tumor necrosis factor-a, interleukin-6 and inducible NOS. 198 Furthermore, resveratrol was also found to have preventive and therapeutic value for the treatment of CVD. 199 It has been established that resveratrol has a role in the prevention of myocardial infarction by maintaining the redox environment during stem cell regeneration in rats. 200 In the presence of resveratrol, induced myocardial ischemia in rats resulted in the regeneration of the myocardium by the stem cells, which would not survive for long in the absence of resveratrol. The resveratrol-induced utilization of APE1/Ref-1 proved responsible/beneficial for maintaining the redox environment in the cells. 200 Supplementation of resveratrol in patients suffering from CVD enhanced the effectiveness of stem cell therapy. 199 Resveratrol also prevented hypertrophy in rats 201 by activating NOS activity, indicating that APE/Ref-1 has a regulatory role in such prevention. Furthermore, rats that were treated with resveratrol exhibited enhanced DNA repair activity because of the upregulated expression of APE1/Ref-1, thus overcoming myocardial stress. 202 Curcumin Curcumin is the active component of Curcuma longa, which is widely used as a spice and in Indian Ayurvedic medicines. This substance acts as a potent anti-inflammatory agent because of its antioxidant activity and ROS scavenging properties. 203 Curcumin's key property of preventing oxidative damage has been implicated in controlling and preventing various human diseases. [204] [205] [206] Curcumin acts by inducing apoptosis or cell cycle arrest in cancer cells 207 and has undergone phase 1 clinical trials for cancer prevention; in these trials, curcumin was found to be safe at intakes of up to 8 g per day. 208 One of the mechanisms through which curcumin displays its anticancer properties is through the inhibition of the mitogen activated protein kinase kinase kinase-Jun-NH2 kinase (MEKK1-JNK) pathway by suppressing the activity of AP-1 and NF-kB signaling molecules. 209 Curcumin may block the downstream signaling cascades of AP-1 and NF-kB by inhibiting the redox function of APE1/Ref-1. The main disadvantage of curcumin use is that the molecule is rapidly metabolized, thereby decreasing its bioavailability. To overcome this problem, an alternative approach has been suggested to increase the bioavailability of curcumin inside the body by supplementing it with piperine. 210 The elevated expression of APE1/Ref-1 in cancer cells leads to the development of drug resistance. Curcumin decreases APE1/ Ref-1 levels in cancer patients. 211 The combined treatment of epigallocatechin-3 gallate (EGCG, a constituent of tea) and curcumin in follicular lymphoma patients decreased the levels of APE1/Ref-1 and TFs to much larger extent than other drugs routinely used in the treatment of this disease. 211 In addition, curcumin exhibits a hepato-protective role and prevents CCl 4 -induced fibrosis in rat models. 211 Therefore, it can be inferred that combination therapy is beneficial and that dietary supplementation is widely important in cancer therapy.
The accumulation of ROS in response to metals results in the oxidation of nitrogenous bases that are present in DNA. Metals such as copper (Cu) and iron (Fe) interact with DNA repair enzymes and oxidize DNA bases; thus, these metals are implicated in NDs. 212 Curcumin acts as a strong metal chelator and has the ability to reverse the inhibition of the NEIL1 caused by metals, such as Cu and Fe, which adversely affect DNA repair in vitro. 212 Curcumin exhibits dual advantages as a potential therapeutic agent by reducing oxidative stress and acting as a metal chelator. Oxidative damage is a common cause of AD, which is associated with the deposition of Ab; as an antioxidant, curcumin has the potential to reduce such stress in AD. 211 In low doses, curcumin reduces the formation of Ab (in both soluble and insoluble forms) and plaque formation in transgenic AD mice. 213 Moreover, curcumin has a strong ability to cross the blood-brain barrier, enabling it to decrease the aggregation of fibrils, resulting in the disaggregation of the Ab and rendering it effective for the prevention and treatment of AD. 214 ( À)-Epigallocatechin-3 gallate Catechins isolated from the leaves of green tea (Camellia sinensis) have a number of beneficial health effects, including anticarcinogenicity, as demonstrated in various tumor models. 215 EGCG has been shown to block the interaction between mouse double minute 2 homolog (MDM2) and p53, thus inhibiting MDM2-mediated p53 ubiquitination, which directly affects DNA damage repair. 216 EGCG exhibits significantly greater anti-invasive properties than other catechins. EGCG reverses the epithelial-to-mesenchymal transition in melanoma cells. 217 EGCG, when used in combination with curcumin, decreased the levels of APE1/Ref-1 and induced complete remission in B-cell non-Hodgkin's lymphoma patients. 215 EGCG was reported to interface with NF-kB activation, thereby resulting in an increased tumor cell response to various NF-kB-activating anticancer drugs, including doxorubicin. Furthermore, EGCG has been shown to inhibit cell migration in melanoma cells after 24 h of treatment in a dose-dependent manner and has been proposed to be associated with cycloxygenase-2 expression and prostaglandin E 2 production. 217 
Decursin
The root of Angelica gigans Nakai (Umbelliferacea) is used in traditional oriental herbal medicine to treat female afflictions and is regarded as a version of ginseng appropriate for females. The pyranocoumarin decursin is one of the main active constituents of Angelica gigans Nakai. 218 Decursin is able to cross the blood-brain barrier and penetrates the CNS. Decursin exhibits neuroprotection against Ab-induced oxidative stress in PC12 cells via nuclear factor-like 2/NF-E2-related factor 2-associated antioxidant-responsive elements. 219 Nuclear factor 2/NF-E2-related factor 2 has been shown to regulate and control the expression of many detoxifying genes, including SOD, CAT, GPx and glutathione S-transferase (GST). 219 Treatment with decursin (0.01-10 mM) has been shown to protect PC12 cells against Ab-induced neurotoxicity. 220 Further, it has been demonstrated that Decursin inhibits the growth and proliferation of human umbilical vein endothelial cells in a dose-dependent manner by delaying the exit from the G1 phase, thus suppressing angiogenesis. 221 Studies are needed to test the effect of decursin on Ab-induced neurotoxicity and its likely role in modulating the functions of APE1/Ref-1 in experimental AD model systems as a potential therapeutic agent because of its ability to cross the blood-brain barrier. 222 Polyphenols (quercetin, luteolin and rosmarinic acid) Quercetin, luteolin and rosmarinic acid are polyphenolic phytochemicals that are present in a variety of food products, including onions, citrus fruit, berries, buckwheat, apples, tea and wine. 223 The protective effect against oxidative DNA damage acts either by preventing the oxidation of DNA (acting as an antioxidant) or by enhancing the frequency of repair by stimulating repair enzymes. The antioxidant properties of quercetin and rosmarinic acid have been examined in various studies. [224] [225] [226] Quercetin protects DNA in Caco-2 cell lines against oxidative DNA damage. 227 Similar results have been found using polyphenols in murine leukemia L1210 cells, HMB2 cells and HepG2 cells. [228] [229] [230] Rosmarinic acid is also capable of protecting against doxorubicin-induced DNA damage in V79 cells. 231 When tested in PC12 cells, the polyphenolic compounds quercetin, luteolin, and in particular, rosmarinic acid conferred protection against oxidative-stressinduced DNA damage by increasing the expression levels of DG 8-oxoguanine glycosylase, thus increasing repair capacity. 232 In contrast, it was found that treatment with rosmarinic acid alone decreased the expression of APE1/Ref-1. 232 In addition, rosmarinic acid and luteolin protected DNA against oxidative damage in Caco-2 cells and in HeLa cells by increasing DNA repair capacity. 233 Together, these studies show that polyphenols can enhance DNA repair activity and prevent oxidative DNA damage, thereby protecting against oxidative DNA damage by modulating the activities of APE1/ Ref-1. Further biochemical and molecular studies are required to understand the mechanism of action of these polyphenols and their effect on modulating the activities of APE1/Ref-1. Center for Comparative Literature, School of Languages, Literature and Culture, Central University of Punjab, Bathinda, India for proofreading the manuscript for typographic and linguistic errors. As a result of the limited focus of the article, many appropriate references could not be included, for which the authors apologize. AKM specially thanks Drs J Regino Perez-Polo and Sankar Mitra at the Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA and their laboratory members for professional development over the years. The CUPB publication number provided for this review is P-102.
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